ArticleBlood2010
Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
Article in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 203 citations in OpenAlex.
- What Is-and What Is Not-Immunogenic Cell Death? Functional Definitions, Experimental Standards, and Common Pitfalls.International journal of molecular sciences · 2026Review
- Low-dose allergen targeting to cDC2 induces long-term protection associated with induction of regulatory-like IL-10Frontiers in immunology · 2026Article
- Development of a dendritic cell-targeted vaccine strategy using proximity-induced conjugation.Theranostics · 2026Article
- Skin immunity and inflammation: cellular interactions and communication.Clinical & translational immunology · 2025Review
- The Dectin-1 and Dectin-2 clusters: C-type lectin receptors with fundamental roles in immunity.EMBO reports · 2024Review
- Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors.Molecular pharmaceutics · 2023Review
- Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder Cancer.Biomedicines · 2023Article
- Current perspective on biological properties of plasmacytoid dendritic cells and dysfunction in gut.Immunity, inflammation and disease · 2023Review
- Cell-targeted vaccines: implications for adaptive immunity.Frontiers in immunology · 2023Review
- Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design.Frontiers in immunology · 2023Review
- Antigen targeting to dendritic cells: Still a place in future immunotherapy?European journal of immunology · 2022Review
- Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy.Vaccines · 2022Review
- CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity.JCI insight · 2022Article
- The aryl hydrocarbon receptor instructs the immunomodulatory profile of a subset of Clec4a4Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Review
- Review
- Review
- Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer.Frontiers in immunology · 2022Review
- Vaccine adjuvants to engage the cross-presentation pathway.Frontiers in immunology · 2022Review
- Unique CLR expression patterns on circulating and tumor-infiltrating DC subsets correlated with clinical outcome in melanoma patients.Frontiers in immunology · 2022Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
Abstract
We evaluated human CD8(+) T-cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. We found the immunoreceptor tyrosine-based inhibitory motif-containing DC immunoreceptor (DCIR) to mediate potent cross-presentation. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8(+) T-cell immunity by all human DC subsets including ex vivo-generated DCs, skin-isolated Langerhans cells, and blood myeloid DCs and plasmacytoid DCs. The delivery of influenza matrix protein (FluMP) through DCIR resulted in expansion of FluMP-specific memory CD8(+) T cells. Enhanced specific CD8(+) T-cell responses were observed when an antigen was delivered to the DCs via DCIR, compared with those induced by a free antigen, or antigen conjugated to a control monoclonal antibody or delivered via DC-SIGN, another lectin receptor. DCIR targeting also induced primary CD8(+) T-cell responses against self (MART-1) and viral (HIV gag) antigens. Addition of Toll-like receptor (TLR) 7/8 agonist enhanced DCIR-mediated cross-presentation as well as cross-priming, particularly when combined with a CD40 signal. TLR7/8 activation was associated with increased expansion of the primed CD8(+) T cells, high production of interferon-γ and tumor necrosis factor-α, and reduced levels of type 2-associated cytokines. Thus, antigen targeting via the human DCIR receptor allows activation of specific CD8(+) T-cell immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.